Loading...
Loading...
BTTX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 797.0K |
| Gross Profit | -797.0K |
| Operating Expense | 7,025.0K |
| Operating I/L | -7,025.0K |
| Other Income/Expense | -563.0K |
| Interest Income | 0.6K |
| Pretax | -7,588.0K |
| Income Tax Expense | 1.0K |
| Net Income/Loss | -7,589.0K |
Better Therapeutics, Inc. specializes in developing software-based prescription digital therapeutics (PDT) for diabetes, heart disease, and other cardiometabolic conditions. Their lead product candidate, BT-001, utilizes digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. Additionally, the company is developing BT-002, a PDT for hypertension, and BT-003, a PDT for hyperlipidemia. These products aim to generate revenue by providing digital therapeutic solutions to patients and healthcare providers, offering an alternative or complement to traditional pharmaceutical treatments for these conditions.
